The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...
The Miyagi Prefectural Government in northeastern Japan invited ambassadors to Japan, representatives, and other officials from 11 countries/regions -- India, South Korea, Vietnam, Kuwait, Cambodia, ...